Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators
Larisa H Cavallari, Emily Cicali, Kristin Wiisanen, Roger B Fillingim, Hrishikesh Chakraborty, Rachel A Myers, Kathryn V Blake, Bolanle Asiyanbola, Jordan F Baye, Wesley H Bronson, Kelsey J Cook, Erica N Elwood, Chancellor F Gray, Yan Gong, Lindsay Hines, Joseph Kannry, Natalie Kucher, Sheryl Lynch, Khoa A Nguyen, Aniwaa Owusu Obeng, Victoria M Pratt, Hernan A Prieto, Michelle Ramos, Azita Sadeghpour, Rajbir Singh, Marc Rosenman, Petr Starostik, Cameron D Thomas, Emma Tillman, Paul R Dexter, Carol R Horowitz, Lori A Orlando, Josh F Peterson, Todd C Skaar, Sara L Van Driest, Simona Volpi, Deepak Voora, Hari K Parvataneni, Julie A Johnson, IGNITE Pragmatic Trials Network, Larisa H Cavallari, Emily Cicali, Kristin Wiisanen, Roger B Fillingim, Hrishikesh Chakraborty, Rachel A Myers, Kathryn V Blake, Bolanle Asiyanbola, Jordan F Baye, Wesley H Bronson, Kelsey J Cook, Erica N Elwood, Chancellor F Gray, Yan Gong, Lindsay Hines, Joseph Kannry, Natalie Kucher, Sheryl Lynch, Khoa A Nguyen, Aniwaa Owusu Obeng, Victoria M Pratt, Hernan A Prieto, Michelle Ramos, Azita Sadeghpour, Rajbir Singh, Marc Rosenman, Petr Starostik, Cameron D Thomas, Emma Tillman, Paul R Dexter, Carol R Horowitz, Lori A Orlando, Josh F Peterson, Todd C Skaar, Sara L Van Driest, Simona Volpi, Deepak Voora, Hari K Parvataneni, Julie A Johnson, IGNITE Pragmatic Trials Network
Abstract
Opioid prescribing for postoperative pain management is challenging because of inter-patient variability in opioid response and concern about opioid addiction. Tramadol, hydrocodone, and codeine depend on the cytochrome P450 2D6 (CYP2D6) enzyme for formation of highly potent metabolites. Individuals with reduced or absent CYP2D6 activity (i.e., intermediate metabolizers [IMs] or poor metabolizers [PMs], respectively) have lower concentrations of potent opioid metabolites and potentially inadequate pain control. The primary objective of this prospective, multicenter, randomized pragmatic trial is to determine the effect of postoperative CYP2D6-guided opioid prescribing on pain control and opioid usage. Up to 2020 participants, age ≥8 years, scheduled to undergo a surgical procedure will be enrolled and randomized to immediate pharmacogenetic testing with clinical decision support (CDS) for CYP2D6 phenotype-guided postoperative pain management (intervention arm) or delayed testing without CDS (control arm). CDS is provided through medical record alerts and/or a pharmacist consult note. For IMs and PM in the intervention arm, CDS includes recommendations to avoid hydrocodone, tramadol, and codeine. Patient-reported pain-related outcomes are collected 10 days and 1, 3, and 6 months after surgery. The primary outcome, a composite of pain intensity and opioid usage at 10 days postsurgery, will be compared in the subgroup of IMs and PMs in the intervention (n = 152) versus the control (n = 152) arm. Secondary end points include prescription pain medication misuse scores and opioid persistence at 6 months. This trial will provide data on the clinical utility of CYP2D6 phenotype-guided opioid selection for improving postoperative pain control and reducing opioid-related risks.
Trial registration: ClinicalTrials.gov NCT04445792.
Conflict of interest statement
The authors declared no competing interests for this work.
© 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Figures
References
- Centers for Disease Control and Prevention . Drug Overdose. US Opioid Dispensing Rate Map. . Accessed January 3, 2022.
- Levy B, Paulozzi L, Mack KA, Jones CM. Trends in opioid analgesic‐prescribing rates by specialty, U.S., 2007–2012. Am J Prev Med. 2015;49:409‐413.
- Ladha KS, Neuman MD, Broms G, et al. Opioid prescribing after surgery in the United States, Canada, and Sweden. JAMA Netw Open. 2019;2:e1910734.
- ClinCalc DrugStats Database . The top 200 drugs of 2019. . Accessed February 10, 2022.
- Cardia L, Calapai G, Quattrone D, et al. Preclinical and clinical pharmacology of hydrocodone for chronic pain: a mini review. Front Pharmacol. 2018;9:1122.
- Crews KR, Monte AA, Huddart R, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther. 2021;110:888‐896.
- Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43:879‐923.
- CYP2D6 frequency table. . Accessed February 28, 2022.
- Smith DM, Weitzel KW, Elsey AR, et al. CYP2D6‐guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet Med. 2019;21:1842‐1850.
- Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, Koren G. Codeine, ultrarapid‐metabolism genotype, and postoperative death. N Engl J Med. 2009;361:827‐828.
- Kelly LE, Rieder M, van den Anker J, et al. More codeine fatalities after tonsillectomy in north American children. Pediatrics. 2012;129:e1343‐e1347.
- Orliaguet G, Hamza J, Couloigner V, et al. A case of respiratory depression in a child with ultrarapid CYP2D6 metabolism after tramadol. Pediatrics. 2015;135:e753‐e755.
- Monte AA, Heard KJ, Campbell J, Hamamura D, Weinshilboum RM, Vasiliou V. The effect of CYP2D6 drug‐drug interactions on hydrocodone effectiveness. Acad Emerg Med. 2014;21:879‐885.
- Thomas CD, Parvataneni HK, Gray CF, et al. A hybrid implementation‐effectiveness randomized trial of CYP2D6‐guided postoperative pain management. Genet Med. 2021;23:621‐628.
- Ginsburg GS, Cavallari LH, Chakraborty H, et al. Establishing the value of genomics in medicine: the IGNITE pragmatic trials network. Genet Med. 2021;23:1185‐1191.
- Cella D, Riley W, Stone A, et al. The patient‐reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self‐reported health outcome item banks: 2005‐2008. J Clin Epidemiol. 2010;63:1179‐1194.
- Patient Reported Outcomes Measurement Information System (PROMIS) HealthMeasures. . Accessed February 11, 2022.
- Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)‐a metadata‐driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377‐381.
- Pratt VM, Cavallari LH, Del Tredici AL, et al. Recommendations for clinical CYP2D6 genotyping allele selection: a joint consensus recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch pharmacogenetics working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy. J Mol Diagn. 2021;23:1047‐1064.
- Food and Drug Administration . Drug development and drug interactions Table of substrates, inhibitors, and inducers. . Accessed January 06, 2022.
- Cicali EJ, Elchynski AL, Cook KJ, et al. How to integrate CYP2D6 Phenoconversion into clinical pharmacogenetics: a tutorial. Clin Pharmacol Ther. 2021;110:677‐687.
- Caudle KE, Sangkuhl K, Whirl‐Carrillo M, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group. Clin Transl Sci. 2020;13:116‐124.
- Thomas CD, Mosley SA, Kim S, et al. Examination of metoprolol pharmacokinetics and pharmacodynamics across CYP2D6 genotype‐derived activity scores. CPT Pharmacometrics Syst Pharmacol. 2020;9:678‐685.
- Adams EH, Breiner S, Cicero TJ, et al. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage. 2006;31:465‐476.
- Preston KL, Jasinski DR, Testa M. Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend. 1991;27:7‐17.
- Gammal RS, Caudle KE, Quinn CT, et al. The case for pharmacogenetics‐guided prescribing of codeine in children. Clin Pharmacol Ther. 2019;105:1300‐1302.
- Andreassen TN, Eftedal I, Klepstad P, et al. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross‐sectional multicentre study. Eur J Clin Pharmacol. 2012;68:55‐64.
- Zwisler ST, Enggaard TP, Mikkelsen S, Brosen K, Sindrup SH. Impact of the CYP2D6 genotype on post‐operative intravenous oxycodone analgesia. Acta Anaesthesiol Scand. 2010;54:232‐240.
- Samer CF, Daali Y, Wagner M, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol. 2010;160:919‐930.
- Dai F, Silverman DG, Chelly JE, Li J, Belfer I, Qin L. Integration of pain score and morphine consumption in analgesic clinical studies. J Pain. 2013;14:767‐777.e8.
- Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain‐United States, 2016. Jama. 2016;315:1624‐1645.
- DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. 1994;13:1341‐1352. discussion 1353‐1346.
- Hermes D, Matthes M, Saka B. Treatment anxiety in oral and maxillofacial surgery. Results of a German multi‐Centre trial. J Craniomaxillofac Surg. 2007;35:316‐321.
- Londhe SB, Shah RV, Patwardhan M, Doshi AP, Londhe SS, Subhedar K. Understanding the apprehension and concern haunting patients before a total knee arthroplasty. Art Ther. 2021;3:14.
- Juprasert JM, Obeid L, Yeo HL. Public perception on opioids & pain management after major surgery. Am J Surg. 2022;223:280‐286.
- Brummett CM, Waljee JF, Goesling J, et al. New persistent opioid Use after Minor and major surgical procedures in US adults. JAMA Surg. 2017;152:e170504.
- Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 National Survey on drug use and health. Ann Intern Med. 2017;167:293‐301.
- Volkow ND, McLellan AT. Opioid abuse in chronic pain‐misconceptions and mitigation strategies. N Engl J Med. 2016;374:1253‐1263.
- Dal‐Re R, Janiaud P, Ioannidis JPA. Real‐world evidence: how pragmatic are randomized controlled trials labeled as pragmatic? BMC Med. 2018;16:49.
- Wick EC, Grant MC, Wu CL. Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: a review. JAMA Surg. 2017;152:691‐697.
- Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther. 1993;54:463‐472.
- Stauble ME, Moore AW, Langman LJ, et al. Hydrocodone in postoperative personalized pain management: pro‐drug or drug? Clin Chim Acta. 2014;429:26‐29.
- Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain‐related function in patients with chronic Back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. Jama. 2018;319:872‐882.
- Krebs EE, Jensen AC, Nugent S, et al. Design, recruitment outcomes, and sample characteristics of the strategies for prescribing analgesics comparative effectiveness (SPACE) trial. Contemp Clin Trials. 2017;62:130‐139.
Source: PubMed